Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)

التفاصيل البيبلوغرافية
العنوان:	Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
المؤلفون:	Zen M., Gatto M., Depascale R., Regola F., Fredi M., Andreoli L., Franceschini F., Urban M. L., Emmi G., Ceccarelli F., Conti F., Bortoluzzi A., Govoni M., Tani C., Mosca M., Ubiali T., Gerosa M., Bozzolo E. P., Canti V., Cardinaletti P., Gabrielli A., Tanti G., Gremese E., De Marchi G., De Vita S., Fasano S., Ciccia F., Pazzola G., Salvarani C., Negrini S., Di Matteo A., De Angelis R., Orsolini G., Rossini M., Faggioli P., Laria A., Piga M., Cauli A., Scarpato S., Rossi F. W., De Paulis A., Brunetta E., Ceribelli A., Selmi C., Prete M., Racanelli V., Vacca A., Bartoloni E., Gerli R., Zanatta E., Larosa M., Saccon F., Doria A., Iaccarino L.
المساهمون:	Zen, M., Gatto, M., Depascale, R., Regola, F., Fredi, M., Andreoli, L., Franceschini, F., Urban, M. L., Emmi, G., Ceccarelli, F., Conti, F., Bortoluzzi, A., Govoni, M., Tani, C., Mosca, M., Ubiali, T., Gerosa, M., Bozzolo, E. P., Canti, V., Cardinaletti, P., Gabrielli, A., Tanti, G., Gremese, E., De Marchi, G., De Vita, S., Fasano, S., Ciccia, F., Pazzola, G., Salvarani, C., Negrini, S., Di Matteo, A., De Angelis, R., Orsolini, G., Rossini, M., Faggioli, P., Laria, A., Piga, M., Cauli, A., Scarpato, S., Rossi, F. W., De Paulis, A., Brunetta, E., Ceribelli, A., Selmi, C., Prete, M., Racanelli, V., Vacca, A., Bartoloni, E., Gerli, R., Zanatta, E., Larosa, M., Saccon, F., Doria, A., Iaccarino, L.
سنة النشر:	2023
المجموعة:	Archivio della ricerca dell'Università di Modena e Reggio Emilia (Unimore: IRIS)
مصطلحات موضوعية:	belimumab, Cutaneous LE Area and Severity Index (CLASI), disease activity score (DAS)-28, low disease activity, remission, systemic lupus erythematosus
الوصف:	Aim. To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods. All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (<2.6) and LDA (≥2.6, ≤3.2), CLASI = 0, 1, and improvement in DAS28 and CLASI indices ≥20%, ≥50%, and ≥70% were evaluated at 6, 12, 24, and 36 months. Results. DAS28 < 2.6 was achieved by 46%, 57%, and 71% of patients at 6, 12, and 24 months, respectively. CLASI = 0 was achieved by 36%, 48%, and 62% of patients at 6, 12, and 24 months, respectively. Belimumab showed a glucocorticoid-sparing effect, being glucocorticoid-free at 8.5%, 15.4%, 25.6%, and 31.6% of patients at 6, 12, 24, and 36 months, respectively. Patients achieving DAS-LDA and CLASI-50 at 6 months had a higher probability of remission at 12 months compared with those who did not (p = 0.034 and p = 0.028, respectively). Conclusions. Belimumab led to clinical improvement in a significant proportion of patients with joint or skin involvement in a real-life setting and was associated with a glucocorticoid-sparing effect. A significant proportion of patients with a partial response at 6 months achieved remission later on during follow-up.
نوع الوثيقة:	article in journal/newspaper
اللغة:	English
Relation:	info:eu-repo/semantics/altIdentifier/wos/WOS:000991070200001; volume:13; issue:4; firstpage:1; lastpage:15; journal:JOURNAL OF PERSONALIZED MEDICINE; https://hdl.handle.net/11380/1365972
DOI:	10.3390/jpm13040691
الاتاحة:	https://hdl.handle.net/11380/1365972 https://doi.org/10.3390/jpm13040691
Rights:	info:eu-repo/semantics/openAccess
رقم الانضمام:	edsbas.1AB5840
قاعدة البيانات:	BASE

View record in BASE

الوصف
DOI:	10.3390/jpm13040691